Articles related to RESEARCH & CLINICAL TRIALS

Ocular Therapeutix announced FDA alignment on a planned fourth-quarter 2026 NDA submission for Axpaxli in wet AMD, based on SOL-1 phase 3 efficacy data and interim safety results from the ongoing SOL-R trial.

An EEG-guided neuromodulation system received FDA clearance for PTSD treatment based on a randomized controlled trial. The platform uses individualized brain activity data to guide therapy, though detailed efficacy results have not been disclosed.

A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.

In a retrospective VA cohort of 669 mCRPC patients who did not progress on initial docetaxel, rechallenge with docetaxel was associated with improved overall survival compared with cabazitaxel after inverse probability of treatment weighting, though short follow-up and inherent selection pressures limit interpretation.

Phase 3 ASCENT-04 data presented at ASCO 2026 showed improved PFS2 for sacituzumab govitecan plus pembrolizumab over chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced triple-negative breast cancer, though an independent expert challenged PFS2 as a valid endpoint for establishing frontline standard-of-care status.

Long-term follow-up from the phase 3 NRG-GY018 trial showed sustained overall survival benefit for pembrolizumab plus carboplatin-paclitaxel in dMMR endometrial cancer at 48 months, while the pMMR OS advantage did not reach statistical significance despite a 9-month median improvement.